Trial Outcomes & Findings for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT NCT05086445)

Last Updated: 2026-07-16

Results Overview

A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

62 participants

Primary outcome timeframe

Baseline Through Follow-Up (Up To Week 15)

Results posted on

2026-07-16

Participant Flow

A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.

Participant milestones

Participant milestones
Measure	Cohort 1a - Placebo Participants received a single oral dose of Placebo in Part A. Participants who completed Part A continued to Part B where they received oral doses of placebo once daily (QD) for 12 weeks.	Cohort 1a - LY3502970 Participants received a single oral dose of 2 mg LY3502970 in Part A. Participants who completed Part A moved to Part B where they received oral doses of LY3502970 QD as follows: 2 milligrams (mg) (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks).	Cohort 2a - Placebo Participants received a single oral dose of Placebo in Part A. Participants who completed Part A continued to Part B where they received oral doses of placebo QD for 12 weeks.	Cohort 2a - LY3502970 Participants received a single oral dose of 3 mg LY3502970 in Part A. Participants who completed Part A moved to Part B where they received oral doses of LY3502970 as follows: 3 mg (2 weeks), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks) and 45 mg (2 weeks).	Cohort 1b - Placebo QD Participants received oral doses of placebo QD for 12 weeks.	Cohort 1b - LY3502970 QD Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks).	Cohort 2b - Placebo QD Participants received oral doses of placebo QD for 12 weeks.	Cohort 2b - LY3502970 QD Participants received oral doses of LY3502970 QD for 12 weeks with doses as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks).	Cohort 3a - Placebo QD Participants received oral doses of placebo QD for 12 weeks.	Cohort 3a - LY3502970 QD Participants received oral doses of LY3502970 QD as follows: 3 mg (2 weeks), 6 mg (2 weeks), and 12 mg (8 weeks).	Cohort 3b - Placebo QD Participants received oral doses of placebo QD for 12 weeks.	Cohort 3b - LY3502970 QD Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), and 12 mg (8 weeks).
Part A STARTED	2	10	2	9	0	0	0	0	0	0	0	0
Part A Received At Least One Dose of Study Drug	2	10	2	9	0	0	0	0	0	0	0	0
Part A COMPLETED	2	8	2	9	0	0	0	0	0	0	0	0
Part A NOT COMPLETED	0	2	0	0	0	0	0	0	0	0	0	0
Part B STARTED	2	10	2	9	1	7	2	9	2	7	2	7
Part B Received At Least One Dose of Study Drug	2	10	2	9	1	7	2	9	2	7	2	7
Part B COMPLETED	1	9	2	9	1	5	2	8	2	6	2	7
Part B NOT COMPLETED	1	1	0	0	0	2	0	1	0	1	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Cohort 1a - Placebo Participants received a single oral dose of Placebo in Part A. Participants who completed Part A continued to Part B where they received oral doses of placebo once daily (QD) for 12 weeks.	Cohort 1a - LY3502970 Participants received a single oral dose of 2 mg LY3502970 in Part A. Participants who completed Part A moved to Part B where they received oral doses of LY3502970 QD as follows: 2 milligrams (mg) (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks).	Cohort 1b - LY3502970 QD Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks).	Cohort 2b - LY3502970 QD Participants received oral doses of LY3502970 QD for 12 weeks with doses as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks).	Cohort 3a - LY3502970 QD Participants received oral doses of LY3502970 QD as follows: 3 mg (2 weeks), 6 mg (2 weeks), and 12 mg (8 weeks).
Part A Adverse Event	0	1	0	0	0
Part A Physician Decision	0	1	0	0	0
Part B Withdrawal by Subject	1	0	2	1	0
Part B Adverse Event	0	1	0	0	1

Baseline Characteristics

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo - Part A n=4 Participants Participants received a single oral dose of Placebo.	2 mg LY3502970 - Part A n=10 Participants Participants received a single oral dose of 2 mg LY3502970.	3 mg LY3502970 - Part A n=9 Participants Participants received a single oral dose of 3 mg LY3502970.	Placebo QD - Part B n=11 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	3/6/12 mg LY3502970 QD - Part B n=7 Participants Participants received oral doses of LY3502970 QD as follows: 3 mg (2 weeks), 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/12 mg LY3502970 QD - Part B n=7 Participants Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/8/12/24 mg LY3502970 QD - Part B n=17 Participants Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 in Part A and completed Part A.	3/6/12/24/36/45 mg LY3502970 QD - Part B n=9 Participants Participants received oral doses of LY3502970 QD as follows: 3 mg (2 weeks), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks) and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 in Part A and completed Part A.	2/3/6/12/24/36/45 mg LY3502970 QD - Part B n=9 Participants Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks).	Total n=83 Participants Total of all reporting groups
Age, Continuous Part A	55.5 years STANDARD_DEVIATION 1.7 • n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	53.1 years STANDARD_DEVIATION 11.7 • n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	57.6 years STANDARD_DEVIATION 5.5 • n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	—	—	—	—	—	—	55.3 years STANDARD_DEVIATION 8.5 • n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Age, Continuous Part B	—	—	—	57.7 years STANDARD_DEVIATION 5.8 • n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	58.0 years STANDARD_DEVIATION 6.8 • n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	56.3 years STANDARD_DEVIATION 8.6 • n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	53.4 years STANDARD_DEVIATION 10.0 • n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	57.6 years STANDARD_DEVIATION 5.5 • n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	57.7 years STANDARD_DEVIATION 7.1 • n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	56.1 years STANDARD_DEVIATION 8 • n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Sex: Female, Male Part A · Female	0 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Sex: Female, Male Part A · Male	4 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	10 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	9 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	23 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Sex: Female, Male Part B · Female	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	1 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	1 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	2 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Sex: Female, Male Part B · Male	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	10 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	6 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	7 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	17 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	9 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	9 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	58 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part A · American Indian or Alaska Native	0 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part A · Asian	4 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	10 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	9 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	23 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part A · Native Hawaiian or Other Pacific Islander	0 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part A · Black or African American	0 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part A · White	0 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part A · More than one race	0 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part A · Unknown or Not Reported	0 Participants n=4 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=10 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=23 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part B · American Indian or Alaska Native	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part B · Asian	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	11 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	7 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	7 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	17 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	9 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	9 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	60 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part B · Native Hawaiian or Other Pacific Islander	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part B · Black or African American	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part B · White	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part B · More than one race	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Race (NIH/OMB) Part B · Unknown or Not Reported	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.	0 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
Region of Enrollment Japan	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	0 Participants A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	11 Participants n=11 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	7 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	7 Participants n=7 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	17 Participants n=17 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	9 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	9 Participants n=9 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.	60 Participants n=60 Participants • A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol. Data are reported separately for Part A and Part B.

PRIMARY outcome

Timeframe: Baseline Through Follow-Up (Up To Week 15)

Population: All participants from Part A and Part B who received at least one dose of study drug. For Part B, as specified in the statistical analysis plan, analyses were performed for the pre-specified treatment groups: placebo, 2(or 3)/3/6/12 mg LY3502970, 2/3/6/8/12/24 mg LY3502970, and 2(or 3)/6/12/24/36/45 mg LY3502970.

Outcome measures

Outcome measures
Measure	Placebo QD - Part B n=4 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	45 mg LY3502970 - Part B n=9 Participants Participants received 45 mg of LY3502970 on Day 84.	24 mg LY3502970 - Part B n=10 Participants Participants received 24 mg of LY3502970 on Day 84.	Placebo QD - Part B n=11 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	2(or 3)/3/6/12 mg LY3502970 QD - Part B n=14 Participants Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/8/12/24 mg LY3502970 QD - Part B n=17 Participants Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A.	2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B n=18 Participants Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration TEAEs	2 Participants	5 Participants	5 Participants	4 Participants	11 Participants	12 Participants	9 Participants
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration SAEs	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)

Population: Part A participants who received at least one dose of LY3502970 and had evaluable PK data.

PK: Cmax of LY3502970.

Outcome measures

Outcome measures
Measure	Placebo QD - Part B n=7 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	45 mg LY3502970 - Part B Participants received 45 mg of LY3502970 on Day 84.	24 mg LY3502970 - Part B n=7 Participants Participants received 24 mg of LY3502970 on Day 84.	Placebo QD - Part B Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	2(or 3)/3/6/12 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/8/12/24 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A.	2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A.
Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 1	9.70 nanograms per milliliter (ng/mL) Geometric Coefficient of Variation 34	—	18.1 nanograms per milliliter (ng/mL) Geometric Coefficient of Variation 38	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)

Population: Part A participants who received at least one dose of LY3502970 and had evaluable PK data.

PK: AUC\[0-tlast\] of LY3502970.

Outcome measures

Outcome measures
Measure	Placebo QD - Part B n=7 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	45 mg LY3502970 - Part B Participants received 45 mg of LY3502970 on Day 84.	24 mg LY3502970 - Part B n=7 Participants Participants received 24 mg of LY3502970 on Day 84.	Placebo QD - Part B Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	2(or 3)/3/6/12 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/8/12/24 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A.	2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A.
Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1	236 nanogram hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 30	—	412 nanogram hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 29	—	—	—	—

SECONDARY outcome

Timeframe: Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)

Population: Part B participants who received at least one dose of study drug and had evaluable PK data. Per protocol, PK analysis was conducted by treatment dose. On Day 84, participants in 12 mg cohort received 12 mg, 24 mg cohort received 24 mg, and 45 mg cohort received 45 mg of LY3502970. Therefore, Cmax of LY3502970 for the respective treatment doses were reported.

PK: Cmax of LY3502970.

Outcome measures

Outcome measures
Measure	Placebo QD - Part B n=12 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	45 mg LY3502970 - Part B n=17 Participants Participants received 45 mg of LY3502970 on Day 84.	24 mg LY3502970 - Part B n=14 Participants Participants received 24 mg of LY3502970 on Day 84.	Placebo QD - Part B Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	2(or 3)/3/6/12 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/8/12/24 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A.	2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A.
Part B: PK: Cmax of LY3502970 on Day 84	112 nanograms per milliliter (ng/mL) Geometric Coefficient of Variation 37	279 nanograms per milliliter (ng/mL) Geometric Coefficient of Variation 53	139 nanograms per milliliter (ng/mL) Geometric Coefficient of Variation 42	—	—	—	—

SECONDARY outcome

Timeframe: Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)

Population: Part B participants who received at least one dose of study drug and had evaluable PK data. Per protocol, PK analysis was conducted by treatment dose. On Day 84, participants in 12 mg cohort received 12 mg, 24 mg cohort received 24 mg, and 45 mg cohort received 45 mg of LY3502970. Therefore, AUC\[0-tlast\] of LY3502970 for the respective treatment doses were reported.

PK: AUC\[0-tlast\] of LY3502970.

Outcome measures

Outcome measures
Measure	Placebo QD - Part B n=12 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	45 mg LY3502970 - Part B n=17 Participants Participants received 45 mg of LY3502970 on Day 84.	24 mg LY3502970 - Part B n=14 Participants Participants received 24 mg of LY3502970 on Day 84.	Placebo QD - Part B Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	2(or 3)/3/6/12 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/8/12/24 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A.	2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A.
Part B: PK: AUC[0-tlast] of LY3502970 on Day 84	5860 nanogram hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 68	11200 nanogram hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 80	7480 nanogram hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 83	—	—	—	—

SECONDARY outcome

Timeframe: Baseline through Day 85

Population: Part B participants who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data. For Part B, as specified in the statistical analysis plan, analyses were performed for the pre-specified treatment groups: placebo, 2(or 3)/3/6/12 mg LY3502970, 2/3/6/8/12/24 mg LY3502970, and 2(or 3)/6/12/24/36/45 mg LY3502970.

Change from Baseline in Fasting Glucose was reported. Least square mean was calculated using the model: Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant was fitted as a random effect.

Outcome measures

Outcome measures
Measure	Placebo QD - Part B n=10 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	45 mg LY3502970 - Part B n=14 Participants Participants received 45 mg of LY3502970 on Day 84.	24 mg LY3502970 - Part B n=12 Participants Participants received 24 mg of LY3502970 on Day 84.	Placebo QD - Part B n=17 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	2(or 3)/3/6/12 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/8/12/24 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A.	2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A.
Change From Baseline in Fasting Glucose	7.40 milligrams per deciliter (mg/dL) Interval -4.08 to 18.89	-61.08 milligrams per deciliter (mg/dL) Interval -67.12 to -55.03	-64.82 milligrams per deciliter (mg/dL) Interval -71.18 to -58.46	-65.56 milligrams per deciliter (mg/dL) Interval -70.91 to -60.22	—	—	—

SECONDARY outcome

Timeframe: Baseline through Day 85

Population: Part B participants who received at least one dose of study drug and had evaluable PD data. For Part B, as specified in the statistical analysis plan, analyses were performed for the pre-specified treatment groups: placebo, 2(or 3)/3/6/12 mg LY3502970, 2/3/6/8/12/24 mg LY3502970, and 2(or 3)/6/12/24/36/45 mg LY3502970.

Change from Baseline in HbA1c. Least square mean was calculated using model Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant is fitted as a random effect

Outcome measures

Outcome measures
Measure	Placebo QD - Part B n=10 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	45 mg LY3502970 - Part B n=14 Participants Participants received 45 mg of LY3502970 on Day 84.	24 mg LY3502970 - Part B n=12 Participants Participants received 24 mg of LY3502970 on Day 84.	Placebo QD - Part B n=17 Participants Participants received oral doses of Placebo QD for 12 weeks. Participants also consisted of those who received placebo and completed Part A.	2(or 3)/3/6/12 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), and 12 mg (8 weeks).	2/3/6/8/12/24 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week), 6 mg (1 week), 8 mg (1 week), 12 mg (1 week) and 24 mg (7 weeks). Participants also consisted of those who received 2 mg of LY3502970 and completed Part A.	2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B Participants received oral doses of LY3502970 QD as follows: 2 mg (1 week), 3 mg (1 week) or 3 mg (2 weeks). This was followed by 6 mg (2 weeks), 12 mg (2 weeks), 24 mg (2 weeks), 36 mg (2 weeks), and 45 mg (2 weeks). Participants also consisted of those who received 3 mg of LY3502970 and completed Part A.
Change From Baseline in Glycated Hemoglobin (HbA1c)	0.67 Percentage of HbA1c Interval 0.2 to 1.14	-2.17 Percentage of HbA1c Interval -2.44 to -1.91	-2.16 Percentage of HbA1c Interval -2.45 to -1.87	-2.28 Percentage of HbA1c Interval -2.52 to -2.04	—	—	—

SECONDARY outcome

Timeframe: Baseline through Day 88

Change from Baseline in Body Weight. Least square mean was calculated using Model: Change from baseline = Baseline + Treatment + Time + Treatment\*Time + participant + Random Error, where participant was fitted as a random effect